<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02864212</url>
  </required_header>
  <id_info>
    <org_study_id>R-2014-785-063</org_study_id>
    <nct_id>NCT02864212</nct_id>
  </id_info>
  <brief_title>Development of a Methodology to Design a High Order Sliding Mode Controller for Drug Dosage</brief_title>
  <official_title>Development of a Methodology to Design a High Order Sliding Mode Controller for Drug Dosage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Coordinación de Investigación en Salud, Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Coordinación de Investigación en Salud, Mexico</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this observational study is to create a data base to extract feature of
      fast-acting drugs that can be monitor in real time to design control strategies based on high
      order sliding mode controller to create a robust drug infusion system.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this observational study is to create a database to extract feature of fast-acting
      drugs that can be monitor in real time to design control strategies based on high order
      sliding mode controller to create a robust drug infusion system.

      The observed drugs in this study are fast acting insulin, propofol and sodium nitroprusside.

      The effect of insulin will be measured by a continuous glucose monitor, the effect of
      propofol by a bispectral index monitor and the the effect of sodium nitroprusside by a
      invasive blood pressure monitor.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose</measure>
    <time_frame>Every 5 minutes during 3 days.</time_frame>
    <description>The glucose will be measured by a continuous glucose monitor. For the group of patients for diabetes.
Note: This protocol has three primary outputs because its objective is to create a database of each output to analyze the response to the associated drug (insulin, propofol and sodium nitroprusside.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bispectral Index</measure>
    <time_frame>Every second during surgery</time_frame>
    <description>Depth of anesthesia will be measured by a Bispectral Index monitor.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Invasive blood pressure</measure>
    <time_frame>Every 5 minutes during surgery</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Diabetes</condition>
  <condition>Hypertension</condition>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Glucose monitoring</arm_group_label>
    <description>Glucose will be monitor in patients using fast-acting insulin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Depth of anesthesia monitoring</arm_group_label>
    <description>Depth of anesthesia will be monitor in patients undergoing cardiac surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Blood pressure monitoring</arm_group_label>
    <description>Invasive blood pressure will be monitor in patients undergoing cardiac surgery.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients scheduled for surgery in the Cardiology Hospital CMNSXXI or treated with
        fast-acting insulin in the Cardiology Hospital CMNSXXI
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  American Society of Anesthesiologists (ASA) physical status I, II, II

        Exclusion Criteria:

          -  Impossibility to measure depth of anesthesia or invasive blood pressure. Impossibility
             of using glucose monitor.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ana Gallardo, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ana Gallardo, Dr.</last_name>
    <phone>+525556276900</phone>
    <phone_ext>22154</phone_ext>
    <email>pancreasartificial@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Unidad de Investigación Médica en Enfermedades Metabólicas IMSS</name>
      <address>
        <city>Mexico</city>
        <state>Mexico City</state>
        <zip>06720</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Gallardo, Dr.</last_name>
      <phone>+525556276900</phone>
      <phone_ext>22154</phone_ext>
      <email>pancreasartificial@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2016</study_first_submitted>
  <study_first_submitted_qc>August 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2016</study_first_posted>
  <last_update_submitted>November 10, 2017</last_update_submitted>
  <last_update_submitted_qc>November 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

